Hong Kong’s Insilico sells cancer drug candidate in potential US$500 million deal

[ad_1] Insilico Medicine, a Hong Kong-based AI-driven drug discovery company that intends to list in Hong Kong after it unveiled an initial public offering plan (IPO) last year, has sold…

Lupin acquires five brands from Italy’s Menarini to strengthen therapy portfolio

[ad_1] Pharmaceutical major Lupin has signed an agreement to acquire five legacy brands in strategic therapy areas—gastroenterology, urology and anti-infectives from Italy-based Menarini Group, according to the regulatory filing by…